Poulton Stuart 4
4 · Karyopharm Therapeutics Inc. · Filed Feb 3, 2026
Research Summary
AI-generated summary of this filing
Karyopharm (KPTI) EVP Stuart Poulton Receives 32,415 RSUs
What Happened Stuart Poulton, EVP & Chief Development Officer of Karyopharm Therapeutics (KPTI), was granted 32,415 restricted stock units (RSUs) on January 31, 2026. The RSUs were recorded at $0.00 per share (award/grant), meaning no cash was exchanged at grant. The RSUs convert into common stock on a one-for-one basis and are subject to time-based vesting.
Key Details
- Transaction date: 2026-01-31 (reported on Form 4 filed 2026-02-03; Period of Report: 2026-01-31)
- Transaction type/code: Award/Grant (A) — 32,415 RSUs @ $0.00 (no cash payment at grant)
- Vesting: 50% vest on 2027-01-31; remaining 50% vest on 2028-01-31 (per footnote)
- RSU conversion: Each RSU converts into one share of KPTI common stock upon vesting
- Shares owned after transaction: Not specified in the filing
- Filing timeliness: Form filed 2026-02-03; no late-filing flag indicated
Context This is a standard equity compensation grant to an executive (time-based RSUs). Grants are compensation and do not indicate an immediate purchase or sale of underlying shares; value to the insider is realized as the RSUs vest and convert to shares (and may be taxable upon vesting).
Insider Transaction Report
- Award
Common Stock
[F1]2026-01-31+32,415→ 99,807 total
Footnotes (1)
- [F1]Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on January 31, 2027, with the remaining 50% vesting on January 31, 2028.